4.7 Article

Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis

Journal

NEUROLOGY
Volume 77, Issue 4, Pages 341-348

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182267b8c

Keywords

-

Funding

  1. Helsinki University Central Hospital (HUCH)
  2. Academy of Finland
  3. The Finnish Medical Foundation
  4. Finnish Medical Association
  5. Boehringer Ingelheim
  6. Lundbeck Inc.
  7. Orion Corporation
  8. Abbott
  9. AstraZeneca
  10. Biomedicum Helsinki Foundation
  11. Finnish-Norwegian Medical Foundation
  12. Emil Aaltonen Foundation
  13. Yrjo Jahnsson Foundation
  14. Finnish Medical Foundation
  15. Genzyme Corporation
  16. Paion AG, Forest Laboratories, Inc.
  17. Finnish Academy of Sciences
  18. European Union
  19. Biocentrum Finland
  20. Biocentrum Helsinki
  21. Sigrid Juselius Foundation
  22. Liv och Halsa
  23. Maire Taponen Foundation

Ask authors/readers for more resources

Objectives: To assess the impact of symptomatic intracerebral hemorrhage (sICH) on outcome of thrombolysis-treated ischemic stroke patients, as additional to recognized prognosticators. Methods: The study cohort included 985 ischemic stroke patients treated with IV thrombolysis at the Helsinki University Central Hospital (1995-2008). In a multivariable model adjusted for baseline stroke severity, age, onset-to-treatment time, baseline glucose, hyperdense cerebral artery sign, and early infarct signs on baseline imaging, and prior modified Rankin Scale (mRS), we calculated risk ratios (RRs) of patients with sICH (separately per Safe Implementation of Thrombolysis in Stroke[SITS]-Monitoring Study, European Cooperative Acute Stroke Study II [ECASS-II], and National Institute of Neurological Disorders and Stroke [NINDS] definitions) for poor 3-month outcome (mRS 3-6) and mortality. Receiver operating characteristic (ROC) curve and integrated discrimination improvement (IDI) evaluated impact of sICH on outcome. Internal cross-validation of the model was done with bootstrap statistics. Results: The frequency of sICH was 2.1% (SITS), 7.0% (ECASS-II), and 9.4% (NINDS). RRs for poor and fatal outcome, respectively, were 1.7 and 4.8 (SITS), 1.6 and 3.8 (ECASS-II), and 1.6 and 3.4 (NINDS). In IDI analyses, sICH improved prediction model for 3-month mRS of 3-6 and 4-6, respectively, by 1.4% and 3.0% (SITS), 4.0% and 5.9% (ECASS-II), and 4.7% and 6.1% (NINDS). In case of 3-month mRS 5-6 and mortality, it was 6.1% and 5.3% (SITS), 11.3% and 9.3% (ECASS-II), and 10.3% and 8.0% (NINDS). ROC analysis revealed similar results. Conclusions: Patients with sICH have increased risk of poor and fatal outcome. Compared with recognized stroke prognosticators, contribution of sICH is smaller. Definition-wise, ECASS-II- and NINDS-based sICH contribute relatively more; ECASS-II has the largest contribution to worst outcomes. Neurology (R) 2011; 77: 341-348

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available